0.22% -0.28

Dopo l'orario di chiusura: 125.75 0.16 +0.13%

Gilead Sciences Inc (GILD)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché GILD Giù? Forum Previsione Frazionamento azionario Storia dei dividendi

Gilead Sciences Inc (GILD)

Gilead Sciences Inc Borsa (GILD) Ultime notizie

Long term debt to total assets ratio of Gilead Sciences, Inc. Shs Cert Deposito Arg Repr 1/4 Sh – BCBA:GILD.CI - TradingView

Gilead Sciences, Inc. Shs Cert Deposito Arg Repr 1/4 Sh Dividends – BCBA:GILD.CI - TradingView

GILD Donates Antiviral Therapy to Support Ebola Response in Ugan - GuruFocus

Gilead donates remdesivir to Uganda for Ebola outbreak response - Investing.com

Gilead donates remdesivir to Uganda for Ebola outbreak response By Investing.com - Investing.com Canada

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief - Business Wire

UniSuper Management Pty Ltd Sells 124,258 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Vaughan David Investments LLC IL Invests $33.80 Million in Gilead Sciences, Inc. $GILD - MarketBeat

Xponance LLC Has $29.15 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat

Gilead Sciences, Inc. $GILD Shares Acquired by Sector Gamma AS - MarketBeat

Swiss National Bank Has $417.34 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat

Te Ahumairangi Investment Management Ltd Sells 8,180 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Meiji Yasuda America Inc Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat

Nuveen LLC Boosts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat

Gilead Sciences, Inc. $GILD Shares Acquired by DJE Kapital AG - MarketBeat

Aviva PLC Acquires 59,782 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Andra AP fonden Cuts Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

SF: Rememberance Work Is Future Work: Gilead Commits $3M For Hiv/Aids Education And Preservation - SFGATE

CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Gilead Sciences, Kite Pharma, Novartis, BMS, Allogene Therapeut - Barchart.com

Gilead Sciences Inc (GILD) Stock Up 3.6% but GF Value Says Overv - GuruFocus

Gilead (GILD) CMO Dietmar Berger converts RSUs and withholds shares for taxes - Stock Titan

Gilead (GILD) CFO exercises 2,796 RSUs and withholds 1,341 shares for taxes - Stock Titan

Gilead (NASDAQ: GILD) officer reports RSU vesting and tax withholding on Form 4 - Stock Titan

Gilead (GILD) CEO Daniel O'Day exercises RSUs and withholds shares for taxes - Stock Titan

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership - Gilead Sciences

Is Gilead (GILD) One of the Top Large Cap Value Stocks to Buy Now? - Insider Monkey

Gilead Sciences Target of Unusually Large Options Trading (NASDAQ:GILD) - MarketBeat

Gilead Sciences Inc Stock (GILD) Moved Up by 3.48% on Jun 11: Key Drivers Unveiled - TradingKey

Johnson Wealth Management LLC Makes New $2.51 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat

Gilead Sciences, Inc. $GILD Shares Bought by Illinois Municipal Retirement Fund - MarketBeat

Gilead Sciences, Inc. $GILD Shares Acquired by LPL Financial LLC - MarketBeat

Cerity Partners LLC Buys 19,673 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Gilead Sciences, Inc. (GILD): a Top Deep Value Stock Making Progress on Pipeline Development - Insider Monkey

Gilead Sciences Inc (GILD) Shares Fall 3.2% -- What GF Score of 76 Tells Investors - GuruFocus

Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Gilead Sciences Inc Stock (GILD) Closed Down by 3.12% on Jun 10: What Investors Need To Know - TradingKey

Can Gilead Sciences HIV Franchise Drive Long-Term Growth? - Yahoo Finance

Motley Fool Asset Management LLC Buys 29,394 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Citi Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $165 - Moomoo

Deutsche Bank AG Decreases Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

Gilead Sciences, Inc. $GILD Shares Sold by BLI Banque de Luxembourg Investments - MarketBeat

4th Circ. Revives Ex-Gilead Worker's Defamation Suit - Law360

What I Wish I Knew About Hepatitis B: Personal Journeys Out of Asia - Gilead Sciences

Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study - Yahoo Finance

Gilead And Merck End Trodelvy-Keytruda Lung Cancer TrialGilead Sciences (NASDAQ:GILD), Merck & Co (NYS - Benzinga

Gilead Balances Trodelvy Setback With Once Weekly HIV Progress - simplywall.st

Gilead’s Mixed Trial News Puts HIV Progress And Oncology Risks In Focus - Yahoo Finance

Merck, Gilead report mixed outcomes in key lung cancer, HIV studies - BioPharma Dive

Calamos Growth & Income Portfolio's Gilead Sciences Inc(GILD) Holding History - GuruFocus

Ex-Gilead Worker Lands New Shot at Defamation Suit Over Firing - Bloomberg Law News

Merck, Gilead score in effort to develop the first weekly HIV pill - Fierce Pharma

As Gilead's Trodelvy stumbles in first-line lung cancer, all eyes turn to Merck, AZ and Daiichi rivals - Fierce Pharma

Gilead and MSD’s once-weekly HIV pill meets primary endpoints in Phase III trials - Clinical Trials Arena

Merck, Gilead serve ‘sweet and sour’ spread after HIV win, cancer stumble - BioSpace

A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $155 to $165 - Moomoo

Cantor Fitzgerald reiterates Gilead stock rating on HIV trial data By Investing.com - Investing.com South Africa

Merck and Gilead discontinue Phase III KEYNOTE-D46/EVOKE-03 study - The Pharma Letter

WINTON GROUP Ltd Sells 56,799 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Franklin Resources Inc. Sells 169,087 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Gilead-MSD once-weekly oral HIV regimen meets Phase III endpoints - European Pharmaceutical Review

Gilead's lung cancer bid for Trodelvy hits wall, but HIV studies deliver better news - FirstWord Pharma

[Press release] Gilead and Merck announce positive topline results from two Phase 3 studies evaluating islatravir/lenacapavir, an oral once-weekly HIV treatment - European AIDS Treatment Group

Merck (MRK) and Gilead Sciences (GILD) Achieve Key Trial Milesto - GuruFocus

Merck, Gilead share positive phase 3 results from combination HIV pill - Seeking Alpha

Gilead and Merck’s Once-Weekly HIV Combo Pill Works in Trials - Bloomberg.com

Merck and Gilead discontinue lung cancer drug trial By Investing.com - Investing.com South Africa

Simile a GILD